Compare Perrigo Co. Plc with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,312 Million (Small Cap)
NA (Loss Making)
NA
0.00%
1.06
-1.21%
0.45
Revenue and Profits:
Net Sales:
1,023 Million
(Quarterly Results - Jun 2026)
Net Profit:
88 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.6%
0%
17.6%
6 Months
-11.76%
0%
-11.76%
1 Year
-45.77%
0%
-45.77%
2 Years
-52.13%
0%
-52.13%
3 Years
-67.51%
0%
-67.51%
4 Years
-69.36%
0%
-69.36%
5 Years
-68.67%
0%
-68.67%
Perrigo Co. Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.43%
EBIT Growth (5y)
-5.72%
EBIT to Interest (avg)
1.61
Debt to EBITDA (avg)
4.82
Net Debt to Equity (avg)
0.74
Sales to Capital Employed (avg)
0.54
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
3.50%
ROE (avg)
1.14%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.45
EV to EBIT
12.88
EV to EBITDA
6.51
EV to Capital Employed
0.73
EV to Sales
1.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.68%
ROE (Latest)
-1.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 91 Schemes (69.92%)
Foreign Institutions
Held by 140 Foreign Institutions (16.92%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
1,022.80
969.10
5.54%
Operating Profit (PBDIT) excl Other Income
218.50
117.50
85.96%
Interest
47.20
50.20
-5.98%
Exceptional Items
-26.10
-396.80
93.42%
Consolidate Net Profit
88.50
-389.90
122.70%
Operating Profit Margin (Excl OI)
38.50%
35.30%
0.32%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 5.54% vs -12.69% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 122.70% vs 72.44% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,253.20
4,373.70
-2.76%
Operating Profit (PBDIT) excl Other Income
681.60
644.00
5.84%
Interest
216.00
248.50
-13.08%
Exceptional Items
-1,397.80
-173.10
-707.51%
Consolidate Net Profit
-1,402.30
-160.70
-772.62%
Operating Profit Margin (Excl OI)
80.90%
72.70%
0.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.76% vs -6.04% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -772.62% vs -3,552.27% in Dec 2024
About Perrigo Co. Plc 
Perrigo Co. Plc
Pharmaceuticals & Biotechnology
Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.
Company Coordinates 
Company Details
The Sharp Building, Hogan Place , DUBLIN None : D02 TY74
Registrar Details






